Welcome to our dedicated page for Biofrontera news (Ticker: BFRI), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. (Nasdaq: BFRI) is a U.S.-based biopharmaceutical company dedicated to the commercialization of innovative dermatological products. Specializing in the treatment of skin conditions such as actinic keratoses and impetigo, Biofrontera focuses on photodynamic therapy (PDT) and topical antibiotics.
One of the company's flagship products is Ameluz®, a prescription drug used in combination with the BF-RhodoLED® lamp series for PDT. Ameluz is approved for the treatment of actinic keratoses, pre-cancerous skin lesions that can develop into skin cancer if left untreated. Another key product in their portfolio is Xepi®, an antibiotic for treating impetigo, a bacterial skin infection.
In recent news, Biofrontera announced record high revenues for 2023, achieving approximately $34.3 million, up 19% compared to 2022. This growth was driven by increased sales of Ameluz and a stronger financial condition, supported by strategic partnerships and clinical trials. The company also reported a successful securities purchase agreement that raised up to $16 million, aimed at advancing product development and expanding indications for Ameluz.
Biofrontera's forward-looking strategy includes reducing the transfer price of Ameluz from 50% to 25% for 2024 and 2025, taking control of U.S. clinical trials, and making significant strides in regulatory approvals with the FDA. For instance, the FDA has commenced a substantive review of a supplementary New Drug Application to increase the approved dosage of Ameluz, indicating the potential for broader usage.
These developments underscore Biofrontera's commitment to enhancing patient care through advanced dermatological therapies and maintaining a robust growth trajectory in the competitive biopharmaceutical landscape.
Biofrontera (NASDAQ:BFRI) reported strong financial results for 2022, with total revenues reaching $28.7 million, a 19% increase from 2021. The fourth quarter revenues grew 11% year-over-year to $10.1 million. Notably, Ameluz revenues exceeded pre-COVID levels, increasing 12% from the 2019 record. The company plans to expand its sales force to 50-55 by 2025, aiming for a 25% revenue growth in 2023. Despite improving metrics, the net loss for 2022 narrowed to $640,000 from $37.7 million in 2021. Adjusted EBITDA remained negative at $18.1 million.
Biofrontera, Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on dermatological treatments, will present at the 35th Annual ROTH Conference in Laguna Nigel, CA, from March 12-14, 2023. CEO Erica Monaco and CFO Fred Leffler will represent the company. Their presentation is scheduled for March 13, 2023, at 8:00 AM PT, and can be viewed live here. An archive will be available after the event. Biofrontera specializes in photodynamic therapy and topical antibiotics for skin conditions, including actinic keratoses and impetigo. For more details, visit www.biofrontera-us.com.
Biofrontera Inc. (NASDAQ:BFRI) has announced that it will release its fourth quarter and full-year 2022 financial results on March 8, 2023, after the market close. A conference call will follow at 4:30 PM ET to discuss the results. Biofrontera specializes in dermatological products, particularly photodynamic therapy and topical antibiotics for conditions like actinic keratoses and impetigo. Investors can access the conference call using a toll-free number or through a webcast provided in the press release.
Biofrontera, Inc. (NASDAQ:BFRI) has been invited to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference from February 21 to 24, 2023. CEO Erica Monaco and CFO Fred Leffler will represent the company, with the presentation scheduled for February 21 at 10:00 AM ET. Attendees can engage in one-on-one meetings with management during the conference. The presentation will be available for live streaming and replay. For further details, investors can reach out via email or register online.
Biofrontera specializes in dermatological products, particularly focusing on photodynamic therapy and topical antibiotics.
Biofrontera Inc. (Nasdaq:BFRI) has announced the initiation of a Phase 3 clinical trial to evaluate the safety and efficacy of Ameluz® and BF-RhodoLED® XL for treating actinic keratosis (AK) on the extremities, neck, and trunk. This study, involving 11 U.S. sites and about 165 patients, aims to meet the growing demand for effective AK therapies, impacting approximately 58 million Americans. Previous trials indicated 91% total clearance of AK on the face and scalp, showcasing Ameluz-PDT's potential to expand its market reach.
Biofrontera Inc. (Nasdaq:BFRI) announced preliminary, unaudited revenues for Q4 and full-year 2022, predicting revenues of approximately $10.2 million to $10.4 million for Q4, marking a 12% increase year-over-year. The total revenue for 2022 is expected to be between $28.7 million and $28.9 million, a record high and a 20% increase from 2021. CEO Erica Monaco expressed optimism about ongoing strategy to expand Ameluz-PDT usage for actinic keratosis treatment. Final results will be reported in March 2023.
Biofrontera Inc. (Nasdaq: BFRI) announced the results from its 2022 Annual Meeting of Stockholders held on December 12, 2022. Stockholders re-elected Loretta M. Wedge as a Class I director until the 2025 Annual Meeting. They approved an amendment to the 2021 Omnibus Incentive Plan, increasing share issuance by 2,589,800 shares. Additionally, Grant Thornton LLP was ratified as the independent accounting firm for the 2022 fiscal year. Detailed voting results are available in a Current Report on Form 8-K filed with the SEC.
Biofrontera (Nasdaq: BFRI) announced its participation in Benchmark’s 11th Annual Discovery One-on-One Investor Conference on December 1, 2022, in New York, NY. CEO Erica Monaco and Executive Chairman Hermann Lübbert will engage with registered investors through one-on-one meetings and small-group sessions. The company specializes in dermatological products, focusing on treatments for actinic keratoses and impetigo.
For more details, please visit Biofrontera's website.
Biofrontera Inc. (NASDAQ: BFRI) will engage in a Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications. The live events are scheduled for November 30, December 5, December 9, and December 19, 2022, aimed at discussing the latest investor presentation and company updates. Key speakers include Prof. Hermann Luebbert, Erica Monaco, and Fred Leffler, who will also participate in a live Q&A. Investors can register for each session and access replays through the company’s investor page post-event.
FAQ
What is the current stock price of Biofrontera (BFRI)?
What is the market cap of Biofrontera (BFRI)?
What does Biofrontera Inc. specialize in?
What are Biofrontera's main products?
What recent financial milestones has Biofrontera achieved?
What strategic partnerships has Biofrontera entered into?
What is the significance of Ameluz in Biofrontera's portfolio?
What recent regulatory progress has Biofrontera made?
How is Biofrontera planning to manage its clinical trials?
What are Biofrontera's plans for future growth?
What is the market focus of Biofrontera?
How does Biofrontera contribute to patient care?
